- The FDA has given Amarin (AMRN) three years of marketing exclusivity for its Vascepa triglyceride-reduction drug.
- Though exclusivity officially only extends through July 25, 2015, Amarin expects it to be "supplemented by a 30-month stay under the Hatch-Waxman Amendments that would be triggered after patent infringement litigation initiated by Amarin" in response to the approval of a generic version of Vascepa.
- Amarin says it's "evaluating whether to challenge" the FDA's decision to give only three years of exclusivity, rather than five, and insists its efforts to bolster Vascepa's patent position have lowered the relative value of marketing exclusivity.
- More on Amarin/Vascepa
From other sites
at CNBC.com (Feb 28, 2014)
at CNBC.com (Oct 17, 2013)
at CNBC.com (Aug 22, 2013)
at CNBC.com (Mar 21, 2013)
at CNBC.com (Jan 17, 2013)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs